Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
N/A N=32 Optive Brand For Day And Night Dry Eye Management
Dry Eye
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score — -12.85 Scores on a scale — p=.001
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
Phase 2 N=123 Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
Dry Eye Disease
Primary: Mean Change in Schirmer's Test Score From Baseline to 84 Days — 10.8; 11.0; 6.0 mm
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
Phase 4 N=15 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Glaucoma · Dry Eyes
Primary: Ocular Surface Staining — 1.65 units on a scale
N/A N=40 Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline in Foreign Body Sensation, Burning/Stinging, Itching, Pain, Stick Feeling, Blurred Vision, Photophobia and Total Ocular Tolerability Score (VAS)…
N/A N=29 Effect of Contact Lenses on Tear Osmolarity in a Controlled Low Humidity Chamber
Myopia · Dry Eye
Primary: Tear Osmolarity — 310; 313; 306 mOsms/L
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
Phase 2 N=9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event
Phase 4 N=39 Nasal Spray Study in Sjogren's Dry Eye Disease
Sjogren's Syndrome · Dry Eye
Primary: Mean Change in Cornea Staining — -1.78 units on a scale
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
Phase 2 N=327 A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
Dry Eye Syndromes
Primary: Percentage of Participants With Systemic Adverse Events (AEs) — 27.7; 8.7; 29.8; 27.1 percentage of participants
Phase 3 N=30 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Dry Eye · Sjogren Syndrome
Primary: Change From Baseline in Ocular Surface Staining — 1.2; 2.4 score on a scale
Phase 4 N=51 Efficacy and Acceptability of Two Lubricant Eye Drops
Dry Eye Syndromes
Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day
Phase 3 N=38 Evaluation of the Effect of Repeated Usage on the Tear Film Characteristics of an Investigational Eye Drop in Dry Eye Sufferers
Dry Eye Syndrome
Primary: Tear Film Evaporation Rate — 26.0 10^-7g/cm^2/sec
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
Phase 3 N=154 Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score — -2.2; -2.7; -4.1; -4.6 FCS score — p=<0.001
Phase 3 N=287 Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dry Eye
Primary: Mean Change in Fluorescein Staining Score From Baseline — -2.12; -2.08 points
N/A N=781 Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Ocular Surface Disease Index (OSDI) Total Score at Baseline — 40.3 Scores on a Scale
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 2 N=183 Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Lacrimation Assessed by Schirmer's Test — 3.02; 2.15; 2.35; 1.35 mm
Phase 3 N=79 A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
Dry Eye Syndromes
Primary: Tolerability Survey Score Using a 100 Unit Visual Analog Scale (VAS) in Period 1 — 255.74; 280.17; 284.89; 255.83 score on a scale
N/A N=20 Acute Comfort of Lubricant Eye Drop FID 111421
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.7; 1.3 Units on a scale
Phase 3 N=43 Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
Dry Eye
Primary: Severity of Dry Eye Symptoms as Assessed by the Dry Eye Questionnaire - 5 (DEQ5) — 6.6; 4.5 score on a scale
Phase 2 N=138 Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants